相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
Sophia B. Georghiou et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance
Thomas Maitre et al.
MICROORGANISMS (2022)
Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study
Iris Finci et al.
LANCET MICROBE (2022)
Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown
Armand Van Deun et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis Results from a Randomized Clinical Trial
Kamunkhwala Gausi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial
Kelly E. Dooley et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis from Mycobacterium tuberculosis
Ankita Punetha et al.
ACS CHEMICAL BIOLOGY (2020)
A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis
Boi-Lam Hong et al.
CLINICAL THERAPEUTICS (2020)
Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations
Jansy Sarathy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti
Kathleen F. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2019)
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
Mohammad H. Al-Shaer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms
Arash Ghodousi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis
Noura M. Al-Mutairi et al.
BMC INFECTIOUS DISEASES (2019)
Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients
Samiksha Ghimire et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Expression analysis of 10 efflux pump genes in multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis clinical isolates
Jalil Kardan-Yamchi et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
Charles A. Peloquin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Successful Treatment with a High-dose Rifampin-containing Regimen for Pulmonary Tuberculosis with a Disputed rpoB Mutation
Dae Hyun Jeong et al.
INTERNAL MEDICINE (2018)
Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study
Matteo Zignol et al.
LANCET INFECTIOUS DISEASES (2018)
Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis
Elizabeth P. Harausz et al.
PLOS MEDICINE (2018)
Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis
Jian Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Mycobacterium tuberculosis Major Facilitator Superfamily Transporters
Ping Li et al.
JOURNAL OF MEMBRANE BIOLOGY (2017)
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
Nicolas Blondiaux et al.
SCIENCE (2017)
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB
L. Rigouts et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis
Jung-Yien Chien et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin
Xia Yu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB
Samiksha Ghimire et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Martin J. Boeree et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Population Modeling and Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Isoniazid in Lungs
L. Lalande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Treatment outcome of patients with isoniazid mono-resistant tuberculosis
J. -Y. Chien et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
Paolo Denti et al.
PLOS ONE (2015)
Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients
Simbarashe P. Zvada et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients
K. J. M. Aung et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2014)
Impact of Fluoroquinolone Resistance on Bactericidal and Sterilizing Activity of a Moxifloxacin-Containing Regimen in Murine Tuberculosis
Aurelie Fillion et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
The Expression of ABC Efflux Pump, Rv1217c-Rv1218c, and Its Association with Multidrug Resistance of Mycobacterium tuberculosis in China
Ke Wang et al.
CURRENT MICROBIOLOGY (2013)
Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard
Armand Van Deun et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial
Rovina Ruslami et al.
LANCET INFECTIOUS DISEASES (2013)
Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis
Diana Machado et al.
PLOS ONE (2012)
Molecular Investigation of Resistance to the Antituberculous Drug Ethionamide in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis
F. Brossier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge
J. van Ingen et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2011)
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Armand Van Deun et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model
Julien Poissy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Detection of rpoB, katG and inhA gene mutations in Mycobacterium tuberculosis clinical isolates from Chongqing as determined by microarray
C. Yao et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Efflux-Pump-Derived Multiple Drug Resistance to Ethambutol Monotherapy in Mycobacterium tuberculosis and the Pharmacokinetics and Pharmacodynamics of Ethambutol
Shashikant Srivastava et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis
Thomas Schon et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Synthetic EthR inhibitors boost antituberculous activity of ethionamide
Nicolas Willand et al.
NATURE MEDICINE (2009)
Extensively Drug-Resistant Tuberculosis in the United States, 1993-2007
N. Sarita Shah et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis
Charles A. Peloquin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Practical applications and feasibility of efflux pump inhibitors in the clinic - A vision for applied use
O Lomovskaya et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional analysis of mutant enzymes
A Aubry et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance
P Domenech et al.
INFECTION AND IMMUNITY (2005)
The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol
R Colangeli et al.
MOLECULAR MICROBIOLOGY (2005)
Rv2686c-rv2687c-rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis
MR Pasca et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator
J Engohang-Ndong et al.
MOLECULAR MICROBIOLOGY (2004)
分享论文
